Previous PostMaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD
Next PostMaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic
